When was Beta Drugs founded?

Beta Drugs was founded in 2005 and raised its 1st funding round 19 years after it was founded.

Where is Beta Drugs located?

Beta Drugs is headquartered in Panchkula, India. It is registered at Village Nandpur, Solan, Baddi, Himachal Pradesh, India, 174101.

Which legal entities is Beta Drugs associated with?

Beta Drugs is associated with BETA DRUGS LIMITED and 1 other.

How many employees does Beta Drugs have?

As of Jan 31, 2025, Beta Drugs has 637 employees, reflecting a 19% year-over-year growth in headcount.

Is Beta Drugs a funded company?

Beta Drugs is a funded company, having raised a total of $***** in its 1st and only funding round, a Post IPO round on Nov 27, 2024.

When was the latest funding round of Beta Drugs?

Beta Drugs' latest funding was a $***** Post IPO round on Nov 27, 2024, with participation from 1 investor. Its primary sector is Oncology. In India, the Oncology sector has seen $20M in funding in 2026 to date.

What is the annual revenue of Beta Drugs?

Annual revenue of Beta Drugs is between ₹100 Cr and ₹500 Cr as on Mar 31, 2025

Where does Beta Drugs rank among its competitors?

Beta Drugs ranks 751st amongst 3287 active competitors, of which 1119 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Beta Drugs?

Beta Drugs' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Beta Drugs - 2026 Company Profile, Team, Funding, Competitors & Financials

Beta Drugs is a public company based in Panchkula (India), founded in 2005 by Vijay Batra. It operates as a Developer of therapeutics for oncology and dermatology. Beta Drugs has raised an undisclosed amount in funding. The company has 3287 active competitors, including 1119 funded and 775 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of therapeutics for oncology and dermatology. It offers nanoparticle –albumin–bound paclitaxel, docetaxel and gemcitabine in the form of tablets, capsules, oral liquids, and injectables. It also provide services including method development, qualification, validation, and transfer, stability protocol development, pre-formulation studies, and others.

Website: www.betadrugslimited.com/
Email ID: *****@betadrugslimited.com
Phone Number: +91 **********
Registered Address: Village Nandpur, Solan, Baddi, Himachal Pradesh, India, 174101

Key Metrics

Founded Year

2005

Location

Panchkula, India

Stage

Public

Latest Funding Round

Post IPO, Nov 27, 2024, $*****

Ranked

751^st among 3287 active competitors

Annual Revenue

₹100 - ₹500 Cr as on Mar 31, 2025

Employee Count

637 as on Jan 31, 2025

Similar Companies

Jazz Pharmaceuticals & 2980 more

Exit Details

Public

View Beta Drugs' full profile

Beta Drugs is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ADLEY FORMULATIONS PRIVATE LIMITED CIN: U24303HR2018PTC076347 , India, Active	Oct 09, 2018	₹100 - ₹500 Cr (As on Mar 31, 2025)	301 (As on Apr 01, 2026)
BETA DRUGS LIMITED CIN: L24230HP2005PLC028969 , India, Active	Sep 21, 2005	₹100 - ₹500 Cr (As on Mar 31, 2025)	453 (As on Apr 01, 2026)

Beta Drugs got listed on Oct 12, 2017.

Click here to take a look at Beta Drugs's IPO in detail

Beta Drugs has raised funding over 1 round. Its latest funding round was a Post IPO round on Nov 27, 2024 for $*****. 1 investor participated in its latest round. Beta Drugs has 1 institutional investor.

Here is the list of recent funding rounds of Beta Drugs:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 27, 2024	5790111	Post IPO	4749587	3347986	9995151	1101654

Access funding benchmarks and valuations. Sign up today!

View details of Beta Drugs's funding rounds and investors

The founders of Beta Drugs is Vijay Batra.

Here are the details of Beta Drugs' key team members:

Vijay Batra: Founder of Beta Drugs.
Contact Info: 1 email address

View details of Beta Drugs's Founder profiles and Board Members

Beta Drugs' employee count trend

Beta Drugs has 637 employees as of Jan 25. The total employee count is 19.0% more than what it was in Jan 24. Here is Beta Drugs's employee count trend over the years:

Uncover Beta Drugs' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Beta Drugs include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Beta Drugs, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
751st	Beta Drugs 2005, Panchkula (India), Public	Developer of therapeutics for oncology and dermatology	-	-	46/100